Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001517022-26-000039
Filing Date
2026-05-07
Accepted
2026-05-07 07:24:30
Documents
95
Period of Report
2026-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q akba-20260331.htm   iXBRL 10-Q 2041721
2 EX-31.1 exhibit311-q12026.htm EX-31.1 10988
3 EX-31.2 exhibit312-q12026.htm EX-31.2 11048
4 EX-32.1 exhibit321-q12026.htm EX-32.1 7561
10 GRAPHIC akba-20260331_g1.gif GRAPHIC 3995
  Complete submission text file 0001517022-26-000039.txt   9711451

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT akba-20260331.xsd EX-101.SCH 85174
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT akba-20260331_cal.xml EX-101.CAL 80809
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT akba-20260331_def.xml EX-101.DEF 368698
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT akba-20260331_lab.xml EX-101.LAB 843314
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT akba-20260331_pre.xml EX-101.PRE 619732
99 EXTRACTED XBRL INSTANCE DOCUMENT akba-20260331_htm.xml XML 1206798
Mailing Address 245 FIRST STREET CAMBRIDGE MA 02142
Business Address 245 FIRST STREET CAMBRIDGE MA 02142 617-871-2098
Akebia Therapeutics, Inc. (Filer) CIK: 0001517022 (see all company filings)

EIN.: 208756903 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36352 | Film No.: 26950866
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)